214 related articles for article (PubMed ID: 30667081)
21. Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library.
Wu Y; Zhou L; Wang Z; Wang X; Zhang R; Zheng L; Kang T
Cancer Biol Med; 2020 Aug; 17(3):782-794. PubMed ID: 32944406
[No Abstract] [Full Text] [Related]
22. SiRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells.
Zhang F; Chen A; Chen J; Yu T; Guo F
Asian Pac J Cancer Prev; 2011; 12(1):239-45. PubMed ID: 21517265
[TBL] [Abstract][Full Text] [Related]
23. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.
Zhang CL; Zhu KP; Shen GQ; Zhu ZS
Tumour Biol; 2016 Feb; 37(2):2737-48. PubMed ID: 26408180
[TBL] [Abstract][Full Text] [Related]
24. Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.
Feng Y; Sassi S; Shen JK; Yang X; Gao Y; Osaka E; Zhang J; Yang S; Yang C; Mankin HJ; Hornicek FJ; Duan Z
J Orthop Res; 2015 Feb; 33(2):199-207. PubMed ID: 25348612
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
26. Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis.
Hansen SA; Hart ML; Busi S; Parker T; Goerndt A; Jones K; Amos-Landgraf JM; Bryda EC
Dis Model Mech; 2016 Oct; 9(10):1139-1146. PubMed ID: 27528400
[TBL] [Abstract][Full Text] [Related]
27. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
Hou J; Cao X; Cheng Y; Wang X
Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells.
Pan W; Wang H; Jianwei R; Ye Z
Cell Physiol Biochem; 2014; 33(2):402-12. PubMed ID: 24556602
[TBL] [Abstract][Full Text] [Related]
29. Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation.
Tanihara F; Hirata M; Nguyen NT; Le QA; Hirano T; Takemoto T; Nakai M; Fuchimoto DI; Otoi T
PLoS One; 2018; 13(10):e0206360. PubMed ID: 30352075
[TBL] [Abstract][Full Text] [Related]
30. Effect of Vinorelbine on cell growth and apoptosis induction in human osteosarcoma in vitro.
Roncuzzi L; Marti G; Baiocchi D; Del Coco R; Cocchi S; Gasperi-Campani A
Oncol Rep; 2006 Jan; 15(1):73-7. PubMed ID: 16328036
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin.
Zou J; Gan M; Mao N; Zhu X; Shi Q; Yang H
Arch Med Res; 2010 Apr; 41(3):162-9. PubMed ID: 20682173
[TBL] [Abstract][Full Text] [Related]
33. [The clonal evolution of osteosarcomas].
Baumhoer D
Pathologe; 2016 Nov; 37(Suppl 2):163-168. PubMed ID: 27651058
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53.
Yoon H; Liyanarachchi S; Wright FA; Davuluri R; Lockman JC; de la Chapelle A; Pellegata NS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15632-7. PubMed ID: 12438652
[TBL] [Abstract][Full Text] [Related]
35. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.
Liu T; Yan Z; Liu Y; Choy E; Hornicek FJ; Mankin H; Duan Z
Cell Physiol Biochem; 2018; 46(3):1218-1230. PubMed ID: 29672299
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis.
Pakos EE; Kyzas PA; Ioannidis JP
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6208-14. PubMed ID: 15448009
[TBL] [Abstract][Full Text] [Related]
37. Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
Liu C; Banister CE; Buckhaults PJ
Cancer Res; 2019 May; 79(9):2392-2403. PubMed ID: 30862715
[TBL] [Abstract][Full Text] [Related]
38. CKM and TERT dual promoters drive CRISPR-dCas9 to specifically inhibit the malignant behavior of osteosarcoma cells.
Hu Y; Zhang H; Guo Z; Zhou J; Zhang W; Gong M; Wu J
Cell Mol Biol Lett; 2023 Jul; 28(1):52. PubMed ID: 37415116
[TBL] [Abstract][Full Text] [Related]
39. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Park HJ; Bae JS; Kim KM; Moon YJ; Park SH; Ha SH; Hussein UK; Zhang Z; Park HS; Park BH; Moon WS; Kim JR; Jang KY
J Exp Clin Cancer Res; 2018 May; 37(1):107. PubMed ID: 29784019
[TBL] [Abstract][Full Text] [Related]
40. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
Stolte B; Iniguez AB; Dharia NV; Robichaud AL; Conway AS; Morgan AM; Alexe G; Schauer NJ; Liu X; Bird GH; Tsherniak A; Vazquez F; Buhrlage SJ; Walensky LD; Stegmaier K
J Exp Med; 2018 Aug; 215(8):2137-2155. PubMed ID: 30045945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
